Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 20 Publications

10 Customer Reviews

  • FACS profiles for cell cycle synchronization of HCT116 cells pulsed with EdU. Asynchronous (AS) HCT116 cells were treated with CDK4/6i (Palbociclib, 2 μM) for 20 hours to arrest in G0/G1 (middle panel), followed by a wash in fresh media for 8 hours to release into S phase (right panel).

    Cell, 2018, 174(5):1127-1142. Palbociclib (PD-0332991) HCl purchased from Selleck.

    PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

    (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

    The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)		 CDK4/CyclinD1 [1]
(Cell-free assay)		 CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 NVzITWhZU2mwYYPlJGF{e2G7 NFXsZ2YzPCCq NWLBdVdzUW6qaXLpeIlwdiCxZjDDSGs1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWmJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxOiEQvF2= NYr6NIl5OjR4NEGxNFM>
COLO205 MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXK3NkBp NXL3e2JpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkCzOkDPxE1? MWWyOFY1OTFyMx?=
U937 M{[xTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;KO|IhcA>? MmHsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjF2IN88US=> M2exNVI1PjRzMUCz
MOLM13 M2\wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7pO|IhcA>? NY\IRpBZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? NXy3eWdGOjR4NEGxNFM>
MOLM13 M4rZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M362d|czKGh? MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO MnLsNlQ3PDFzMEO=
MDA-MB-435 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf3PJozPCCq M1vK[WlEPTB;MD6xOkDPxE1? M4\iTVE2QDBzOEOx
K562 M3jPOGN6fG:2b4jpZ{BCe3OjeR?= M{XWNFk3KGh? NXjISIE4TE2VTx?= NU[4Z4VYUUN3ME2yJO69VQ>? M3zDflI1PDF5NU[2
DU145 NYDvTI1RS3m2b4TvfIlkKEG|c3H5 MnHzPVYhcA>? M1e3dmROW09? NX3KUY5{UUN3ME23MlUh|ryP MVSyOFQyPzV4Nh?=
MDA-MB-231 M17KfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[xJO69VQ>? MVuyOEBp M4HWZ2ROW09? MkD3R4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl M3e0fVI1PDF5NU[2
MCF7 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rNflEh|ryP MYeyOEBp NHX6dGtFVVOR MorGR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl MVyyOFQyPzV4Nh?=
MCF7 NInNepRMcW6jc3WgRZN{[Xl? Mke0OUDPxE1? NVLibnU1OjRiaB?= M4nBV2ROW09? MoXCTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= NF2xZ3ozPDRzN{W2Oi=>
MDA-MB-231 MX3LbY5ie2ViQYPzZZk> M2mxWVUh|ryP MnrPNlQhcA>? NUXHN4cxTE2VTx?= NFn2OZRKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw NXf0b29yOjR2MUe1OlY>
MDA-MB-231 NXHKPZVNTnWwY4Tpc44hSXO|YYm= M1XQfFEuOTBizszN M4D3OVI1KGh? M4L6TWROW09? M{\yVIRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= NU\4OoxzOjR2MUe1OlY>
MCF7 MWTGeY5kfGmxbjDBd5NigQ>? MnPRNU0yOCEQvF2= NYrUUo1XOjRiaB?= MYTEUXNQ NEjMOmJld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W= NIK2dWczPDRzN{W2Oi=>
MDA-MB-231 NGX0SGhHfW6ldHnvckBCe3OjeR?= MXqwMlUuOSEQvF2= MWW0PEBp MXXEUXNQ NYLQZXNycGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V? MoTTNlQ1OTd3Nk[=
MCF7 NEnjZnhHfW6ldHnvckBCe3OjeR?= MnvENE42NTFizszN MnX4OFghcA>? NXrXNZRoTE2VTx?= MYLoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=> NFzGcXgzPDRzN{W2Oi=>
697 M1[4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF2OD6zPEBvVQ>? NFrmXHhUSU6JRWK=
P12-ICHIKAWA NIrUbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTl4LkC0JI5O M1;WPHNCVkeHUh?=
NB69 M4rHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvsU4FQUUN3ME2xOlEvQCCwTR?= NWXmUFJ{W0GQR1XS
EoL-1 NXT2OJd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HXc2lEPTB;MUi3MlI3KG6P NEfOTYJUSU6JRWK=
BHT-101 M{\rdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\sTWM2OD1zOUiuNlUhdk1? NVnyTFRiW0GQR1XS
SK-NEP-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm2UJlKSzVyPUKyNE4xOiCwTR?= NYDaWINYW0GQR1XS
MHH-NB-11 NIXyPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XabWlEPTB;MkKwMlE6KG6P NXHvO2RZW0GQR1XS
AsPC-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[5cmRKSzVyPUK1Nk42OyCwTR?= M1HUVXNCVkeHUh?=
ES1 M3vr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\sTWM2OD1{NU[uNlUhdk1? NGP5UY9USU6JRWK=
LAMA-84 M4TXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[3TplKSzVyPUK1PE4yQSCwTR?= NX\XXVQ4W0GQR1XS
MOLT-16 M4\VN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f4PGlEPTB;MkW4MlQ6KG6P NYPjclZOW0GQR1XS
ES7 NWrzR5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTjUmJKSzVyPUK3N{4xQSCwTR?= MUHTRW5ITVJ?
KY821 M1;0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;3OWlEPTB;M{G0MlEhdk1? NVLJeJd5W0GQR1XS
RT-112 NVHNZXhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ntN2lEPTB;M{KxMlA2KG6P MX\TRW5ITVJ?
HL-60 NEHPU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTN2MD62OkBvVQ>? NXOycGxDW0GQR1XS
MOLT-4 NHzaZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTN2NT6xN{BvVQ>? NHzYV|VUSU6JRWK=
KARPAS-45 NGDxVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\NcYxsUUN3ME2zO|YvOTZibl2= MkXvV2FPT0WU
SK-N-AS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rFWmlEPTB;M{i3Mlg{KG6P NFqwOJdUSU6JRWK=
CTB-1 M3:yPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrMT5JiUUN3ME20NFUvODJibl2= MUjTRW5ITVJ?
NKM-1 Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:xSIFXUUN3ME20NVEvQDlibl2= M3PWUnNCVkeHUh?=
HTC-C3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjFblhHUUN3ME20N|IvQTVibl2= NFqyVJlUSU6JRWK=
BE-13 NHXvWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTR2ND6yO{BvVQ>? MVTTRW5ITVJ?
KOSC-2 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX25S4U2UUN3ME20OlYvQSCwTR?= NEO4UZVUSU6JRWK=
NB14 M1PJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC5SFNMUUN3ME20PFMvPThibl2= Mnn5V2FPT0WU
CAL-27 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmxTWM2OD12OUSuOVkhdk1? M2D6NXNCVkeHUh?=
H9 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13ZWWlEPTB;NEm1MlQ{KG6P Ml;nV2FPT0WU
RS4-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX6XZZKSzVyPUWwOE44OyCwTR?= NYf5NmVZW0GQR1XS
PA-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPYTYFWUUN3ME21NFkvQDZibl2= NWP5TFFIW0GQR1XS
MV-4-11 NFvEdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPFXIQ4UUN3ME21NVMvQDVibl2= NVvF[Id5W0GQR1XS
OS-RC-2 NVLJXHdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzabG1oUUN3ME21NlEvPjJibl2= NYX6UXpHW0GQR1XS
RPMI-8226 M4XqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLWTWM2OD13Mk[uPFYhdk1? NFjNZndUSU6JRWK=
HGC-27 NWnvWm9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[2TWM2OD13NkSuPVkhdk1? M3nCbXNCVkeHUh?=
CHP-212 MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3oPJNKSzVyPUW5N{42QSCwTR?= MUfTRW5ITVJ?
NB10 NX7zbHhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHBRVRKSzVyPUW5PU4yQCCwTR?= NG\QUllUSU6JRWK=
HH NH7PUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf6ZlhKSzVyPUW5PU41OyCwTR?= M2fHTnNCVkeHUh?=
EW-16 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjwWFBZUUN3ME22NFMvPTJibl2= NXHx[FMyW0GQR1XS
ES8 NVfnemFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITkRXRKSzVyPU[wOU4zOSCwTR?= M1nzWXNCVkeHUh?=
HAL-01 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH5NlNtUUN3ME22NFUvPjdibl2= M1nic3NCVkeHUh?=
A204 M{CxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf1UpVOUUN3ME22N|MvQTFibl2= NVHhPHo2W0GQR1XS
MHH-PREB-1 M4PJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvDZ2xKSzVyPU[zOk46QSCwTR?= MXrTRW5ITVJ?
EM-2 M3jmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPEPZdyUUN3ME22OVAvPjRibl2= M1vsWHNCVkeHUh?=
BV-173 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jWWWlEPTB;NkWyMlQ5KG6P M4HJc3NCVkeHUh?=
ONS-76 NFjndnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS5TWM2OD14N{euPFIhdk1? MVXTRW5ITVJ?
KM-H2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTZ7NT61OEBvVQ>? NXe1ZnNzW0GQR1XS
D-263MG MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTdzNz6xNkBvVQ>? NFLIcJlUSU6JRWK=
ES3 MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HPPWlEPTB;N{K4Mlk{KG6P NH[5NXlUSU6JRWK=
VA-ES-BJ MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\ZSJlKSzVyPUezNk4zPyCwTR?= M3TvRnNCVkeHUh?=
NBsusSR M3f1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvTWI5KSzVyPUe0Nk46QSCwTR?= NXLQPZFLW0GQR1XS
NCI-H520 NGTpRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn1bWlGUUN3ME23OFYvPTJibl2= NGexSoxUSU6JRWK=
ES5 M3LEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTd3Mj64JI5O Mn7VV2FPT0WU
T-24 M4LHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlmxTWM2OD15N{iuO|Ehdk1? Ml36V2FPT0WU
SW962 MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDkTWM2OD16MEiuOlMhdk1? NEXJfpBUSU6JRWK=
EW-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TtW2lEPTB;OEC4Mlc3KG6P NIryOWNUSU6JRWK=
RXF393 NVu5O4VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRThzMj63PUBvVQ>? NXW1[pJCW0GQR1XS
U251 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTLUplyUUN3ME24NVMvQDhibl2= MlO2V2FPT0WU
CAMA-1 M2\FPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHjcYhKSzVyPUizN{46PCCwTR?= M1P6U3NCVkeHUh?=
JVM-3 M1XKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXsdWFKSzVyPUi1NU44QCCwTR?= NWiwSnJPW0GQR1XS
COLO-800 Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDIfo5KSzVyPUi5O{44QCCwTR?= MUTTRW5ITVJ?
OVCAR-5 NYHuNZJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\HTWM2OD17MECuNUBvVQ>? MULTRW5ITVJ?
LB1047-RCC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTl{Nz61OkBvVQ>? NF\VS4VUSU6JRWK=
SW954 MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTl{OT60NUBvVQ>? MnjGV2FPT0WU
J-RT3-T3-5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTl|Nj6wOkBvVQ>? NILPboFUSU6JRWK=
Mewo NYX6fFNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTSTWM2OD17M{[uOkBvVQ>? M4fUdXNCVkeHUh?=
NCI-H1770 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\JVGlvUUN3ME25OFAvPTVibl2= NXHtcIhKW0GQR1XS
HO-1-N-1 M1:wRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPPSJFKSzVyPUm2Nk45OSCwTR?= NVHjfFI4W0GQR1XS
HSC-3 M130emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTl4Nj60PEBvVQ>? MoXMV2FPT0WU
TYK-nu NWX5RmhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX2TWM2OD17OUiuNlUhdk1? MlTYV2FPT0WU
KYSE-150 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LZS2lEPTB;MT6wNFA4PiEQvF2= NUDxOYFHW0GQR1XS
SN12C NV34ZWxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkCzTWM2OD1zLkCwPFc2KM7:TR?= MnW1V2FPT0WU
MOLT-13 M3joWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17wN2lEPTB;MT6wNVQzOSEQvF2= M3zw[3NCVkeHUh?=
TE-11 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnoTWM2OD1zLkC0PFEzKM7:TR?= MnjQV2FPT0WU
DB NGXkfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojxTWM2OD1zLkC3Nlc{KM7:TR?= M{TD[nNCVkeHUh?=
CAL-39 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrId4ZKSzVyPUGuNFc2OjJizszN M1rZfXNCVkeHUh?=
A3-KAW MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwMEi0NFgh|ryP NFPNUHZUSU6JRWK=
CHP-134 NWC3V|BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LFdmlEPTB;MT6xNVgxPyEQvF2= MnLXV2FPT0WU
TGW MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrLOGlbUUN3ME2xMlEzOzl3IN88US=> M3;zNXNCVkeHUh?=
QIMR-WIL MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFwMUOxN|Qh|ryP MofMV2FPT0WU
NCI-SNU-1 NX;nfGZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfVXVRKSzVyPUGuNVY{PTRizszN NI[xeY9USU6JRWK=
CGTH-W-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[yOlBQUUN3ME2xMlE4OTh4IN88US=> MmnzV2FPT0WU
MHH-ES-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFwMUe5PFYh|ryP MmPDV2FPT0WU
LB2241-RCC NGHZNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fNR2lEPTB;MT6xPFYzKM7:TR?= MkmxV2FPT0WU
ML-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7pVJJKSzVyPUGuNlA4OzRizszN MX;TRW5ITVJ?
COR-L23 NFXEbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljDTWM2OD1zLkKyPVM{KM7:TR?= MlHIV2FPT0WU
BFTC-905 M{\UTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXDUpNCUUN3ME2xMlI1OjZ5IN88US=> M{exNnNCVkeHUh?=
Hs-578-T NIn3bYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLUe4hKSzVyPUGuNlU5OTdizszN NWTtd4FLW0GQR1XS
KG-1 NXSycod5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDTcYZKSzVyPUGuNlY3QDZizszN M4rw[HNCVkeHUh?=
HEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjQcHd[UUN3ME2xMlI6OzN6IN88US=> MlTRV2FPT0WU
A549 NYqxS5B1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfkS2lKSzVyPUGuNlk{QTlizszN NFrpV29USU6JRWK=
COLO-741 NXfvUYpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLSSVBKSzVyPUGuN|IxQDlizszN M17QZXNCVkeHUh?=
PC-3 M17RWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTFwM{WyNlEh|ryP M{\ifHNCVkeHUh?=
HOS Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHxXpV{UUN3ME2xMlM2Ojl4IN88US=> MnLxV2FPT0WU
HT-1080 NX3DZmlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHSTWM2OD1zLkO3OVE6KM7:TR?= MmPqV2FPT0WU
TE-8 M2rKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrYPIhKSzVyPUGuOFE4PzRizszN NILtTmJUSU6JRWK=
BHY NETidWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;zWJNKSzVyPUGuOFY6OjNizszN M{HPeHNCVkeHUh?=
BB65-RCC MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjOSI51UUN3ME2xMlUxPTJ6IN88US=> NHrXZmtUSU6JRWK=
HN MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Dad2lEPTB;MT61OFA4OSEQvF2= NXnMNIpVW0GQR1XS
NCI-H441 NH\QPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTFwNUS5NFch|ryP MYfTRW5ITVJ?
RPMI-8866 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL2TWM2OD1zLkW4OVA4KM7:TR?= M3;QZ3NCVkeHUh?=
CAL-62 MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPRTWM2OD1zLk[wPFYzKM7:TR?= NILaNoVUSU6JRWK=
MG-63 NH7yN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rqR2lEPTB;MT62NVgyOyEQvF2= MlrQV2FPT0WU
SK-LU-1 M2PrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3mxbGlEPTB;MT62NlE2OiEQvF2= MWLTRW5ITVJ?
BCPAP NXfCemZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfqN2hGUUN3ME2xMlY3PDV5IN88US=> MWHTRW5ITVJ?
22RV1 MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zNSWlEPTB;MT62O|g1OyEQvF2= Ml6zV2FPT0WU
T47D NVn1ZVRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLzV4t3UUN3ME2xMlY5ODZzIN88US=> NFe1N|FUSU6JRWK=
MSTO-211H NU[1ZXA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPKTWM2OD1zLk[5OlA{KM7:TR?= NWnLbYl3W0GQR1XS
DEL MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYmwNoVjUUN3ME2xMlcxOjd|IN88US=> MV7TRW5ITVJ?
H4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO2TWM2OD1zLkezNlEzKM7:TR?= MoDrV2FPT0WU
CAL-51 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFwN{S4OVUh|ryP NXHxeohjW0GQR1XS
ABC-1 NG\CVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HnW2lEPTB;MT63PFU5OiEQvF2= NIXXNZhUSU6JRWK=
MZ2-MEL NHjIW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qwZWlEPTB;MT63PVU1OiEQvF2= NWDEOZkyW0GQR1XS
YKG-1 NGXidHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwOEGwOlEh|ryP MVfTRW5ITVJ?
KM12 NUf0cHRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O5eWlEPTB;MT64NVYxOiEQvF2= NEizbnBUSU6JRWK=
L-363 M17rU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13reGlEPTB;MT64O|QyOiEQvF2= MX7TRW5ITVJ?
KU812 MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\mSWlEPTB;MT64PVI5OiEQvF2= MYfTRW5ITVJ?
LOXIMVI NWPtfWx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXY[4RLUUN3ME2xMlkyOjJ6IN88US=> Mn;UV2FPT0WU
G-401 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\mTWM2OD1zLkmyOFI5KM7:TR?= NYSxb5ZkW0GQR1XS
SW780 NXrsb3lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXnTWM2OD1zLkm2NlQ3KM7:TR?= NGezOYpUSU6JRWK=
SW872 NEXjfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37QXWlEPTB;MT65PFM{KM7:TR?= M2rjV3NCVkeHUh?=
NB7 M{fJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW1TWM2OD1zLkm5N|I{KM7:TR?= MWfTRW5ITVJ?
T98G NGT5[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJwMEC2OlYh|ryP NVvEUHlPW0GQR1XS
SW1710 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH24N2FKSzVyPUKuNFY6PDVizszN NHzHXWtUSU6JRWK=
NCI-H1573 NWPidZpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn1XJRKSzVyPUKuNFczQThizszN M{CwXHNCVkeHUh?=
KE-37 MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LhTWlEPTB;Mj6wPFk2OSEQvF2= NYHoWoZbW0GQR1XS
786-0 NHnpNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf4eIZKSzVyPUKuNVU1OzlizszN Mk\jV2FPT0WU
SAS MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJwMkCzO|Qh|ryP NFvObopUSU6JRWK=
CAL-54 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ixOmlEPTB;Mj6yNFQyOyEQvF2= MnXGV2FPT0WU
SF268 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYmyRlJCUUN3ME2yMlI{OTJ{IN88US=> MkX3V2FPT0WU
SW620 NIHNSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJwMk[xOlkh|ryP MWrTRW5ITVJ?
MN-60 NVrWSmZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJwM{GwOkDPxE1? NH6xZmtUSU6JRWK=
EFO-27 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwM{KwOVgh|ryP NISybGVUSU6JRWK=
NCI-H747 NHPleHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHFOYxYUUN3ME2yMlMzOTl7IN88US=> NIPaephUSU6JRWK=
HCC2218 M1PwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\IOItKSzVyPUKuN|U{PzRizszN NXWzdGVDW0GQR1XS
MIA-PaCa-2 M4S0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nMVGlEPTB;Mj6zOlQ{PyEQvF2= NVf5VnA1W0GQR1XS
SJSA-1 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLJTWM2OD1{LkO3O|k3KM7:TR?= M1zK[3NCVkeHUh?=
RKO MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TKbWlEPTB;Mj6zPFQ6PiEQvF2= MVPTRW5ITVJ?
NB6 NWrEVZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LGcmlEPTB;Mj60NFM4PCEQvF2= MYPTRW5ITVJ?
ES4 M3zIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLMTWM2OD1{LkS1OFIzKM7:TR?= MWHTRW5ITVJ?
EGI-1 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XmSGlEPTB;Mj60Olg5OyEQvF2= Ml\1V2FPT0WU
CTV-1 M{HLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LCb2lEPTB;Mj61Nlc4OyEQvF2= NEC1NWpUSU6JRWK=
NCI-H1355 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJwNUW5OVEh|ryP M1nMT3NCVkeHUh?=
GT3TKB NXn1b5VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGxTWM2OD1{LkW5NVk6KM7:TR?= NVLDSJNtW0GQR1XS
SK-HEP-1 NEWwe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvEOYRmUUN3ME2yMlU6OjZ4IN88US=> MofoV2FPT0WU
GAMG MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrVTWM2OD1{LkW5N|k1KM7:TR?= NVLaRY9RW0GQR1XS
SK-MES-1 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jyZWlEPTB;Mj62NVgxOyEQvF2= NELnTW1USU6JRWK=
RO82-W-1 M1\2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L0W2lEPTB;Mj62NlA2PyEQvF2= MmHOV2FPT0WU
ECC10 Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLFNm1KSzVyPUKuO|AzODZizszN Mn7GV2FPT0WU
MCF7 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7qTWM2OD1{LkexOFY1KM7:TR?= MYjTRW5ITVJ?
D-283MED MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nRWWlEPTB;Mj63NlQ{KM7:TR?= M3zkWnNCVkeHUh?=
RPMI-7951 M2THVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJwN{W2PVQh|ryP MlToV2FPT0WU
Ramos-2G6-4C10 NHnEN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWyNolKSzVyPUKuO|cxQTlizszN M{\BZXNCVkeHUh?=
KGN NF3tOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPD[4hKSzVyPUKuPFE5QDRizszN M3u0RnNCVkeHUh?=
NUGC-3 NXvIUHlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHkUnNtUUN3ME2yMlgzPTB3IN88US=> MkT4V2FPT0WU
NCI-H292 NFPYPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJwOEWwOVMh|ryP M1\uOHNCVkeHUh?=
Becker NI\RbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJwOUW4N|Ih|ryP M2\5RnNCVkeHUh?=
NCI-H1299 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTNwMEWyOlMh|ryP NX\aNIhFW0GQR1XS
ETK-1 NU[0Xm5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTNwMEW0N{DPxE1? MmXBV2FPT0WU
TK10 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P3WmlEPTB;Mz6yNFE3PSEQvF2= MlvFV2FPT0WU
VMRC-RCZ NVXTXIpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPLTWM2OD1|LkO2OFg5KM7:TR?= MoP6V2FPT0WU
YH-13 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXB[JNKSzVyPUOuOFQxPzlizszN NWP3PVRXW0GQR1XS
DU-145 NF\IZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTNwNE[yOlkh|ryP M1HTUnNCVkeHUh?=
SW1088 MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn1SHpKSzVyPUOuOFc1PyEQvF2= MV7TRW5ITVJ?
HOP-92 NWK0UHJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED3fHNKSzVyPUOuOVA{PDJizszN MXvTRW5ITVJ?
KP-N-YS NH\WZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTNwNkKxN|kh|ryP NF6xUndUSU6JRWK=
NCI-H460 NG\WUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n5UmlEPTB;Mz62Olc{KM7:TR?= MXXTRW5ITVJ?
U-2-OS NWP4Wmw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHpbHlVUUN3ME2zMlczPTN3IN88US=> MVzTRW5ITVJ?
A101D MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonITWM2OD1|Lke2PVM3KM7:TR?= M2DzcnNCVkeHUh?=
MDA-MB-231 NGfQT2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Tt[2lEPTB;Mz64NVk2OSEQvF2= NHPSNJZUSU6JRWK=
IST-MES1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fkfGlEPTB;Mz64N|Ih|ryP MVvTRW5ITVJ?
COR-L105 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRwMEG4JO69VQ>? MlfCV2FPT0WU
NCI-H1437 NV3Gb3JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXleXRKSzVyPUSuNFI{ODJizszN NUP6RYdrW0GQR1XS
CAL-85-1 NXnhXG8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHznVWhKSzVyPUSuNFI1PjFizszN NGXDVHFUSU6JRWK=
MZ1-PC NHr6VIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3WTWM2OD12LkG4OVU3KM7:TR?= MorFV2FPT0WU
VM-CUB-1 NHrMOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nUcWlEPTB;ND6zNVI5PCEQvF2= M{D6PHNCVkeHUh?=
CHL-1 NHi1V|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\SO2lEPTB;ND6zNlE3QSEQvF2= NVqxd4RCW0GQR1XS
MDA-MB-361 MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTRwM{OxOVMh|ryP NUDxO2FvW0GQR1XS
NCI-H661 NF\tSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXz[3lHUUN3ME20MlUxODl{IN88US=> NHWxN2hUSU6JRWK=
EW-11 M1vGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTRwNUKyN|Eh|ryP MVjTRW5ITVJ?
BEN M{e3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH6TWM2OD12LkWyPFE2KM7:TR?= MUHTRW5ITVJ?
BFTC-909 NGLycnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jKSGlEPTB;ND61OlI4PSEQvF2= NEfjendUSU6JRWK=
NCI-H2087 M2HuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTRwNUixOlQh|ryP Mn64V2FPT0WU
RVH-421 NXzGWnp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\MNm9KSzVyPUSuOlY3QSEQvF2= M2LO[nNCVkeHUh?=
P30-OHK MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjoO2d5UUN3ME20MlY5ODB6IN88US=> NILwbFVUSU6JRWK=
NCI-H28 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTRwOEG2OlEh|ryP M{DxNXNCVkeHUh?=
ES6 Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLDTWM2OD12LkizNFE3KM7:TR?= NXzGNYc4W0GQR1XS
769-P MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHlV4lKSzVyPUSuPFU6OjZizszN NGjYVXdUSU6JRWK=
OE33 NXvlNpBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW4O5VKSzVyPUSuPFgyPjFizszN MnvCV2FPT0WU
SW982 MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LjSWlEPTB;ND65OVA3OSEQvF2= M1nOcHNCVkeHUh?=
A388 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nWXWlEPTB;NT6wNlk5OyEQvF2= NXL1N3o5W0GQR1XS
TI-73 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjZcplKSzVyPUWuNFYyQTRizszN NILZXFBUSU6JRWK=
HCT-116 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonpTWM2OD13LkC5PFg6KM7:TR?= NY\KNVg5W0GQR1XS
HuP-T3 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\wTWM2OD13LkG4O|A6KM7:TR?= M1rkSnNCVkeHUh?=
G-402 M1LrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTrS5FrUUN3ME21MlE6PDF4IN88US=> M1rkeXNCVkeHUh?=
NCI-H1792 M4j4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17zTGlEPTB;NT6yOFYzOiEQvF2= NFXKS3hUSU6JRWK=
NCI-H209 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli5TWM2OD13LkK1PVQzKM7:TR?= NGL0fHJUSU6JRWK=
NCI-H1650 NXfEZVRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG1TWM2OD13LkOwOlM1KM7:TR?= NHu0c5RUSU6JRWK=
LCLC-97TM1 NIryeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7rT2xMUUN3ME21MlMyQDB6IN88US=> NYnacpE2W0GQR1XS
S-117 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzDd4JpUUN3ME21MlM3QTd4IN88US=> NXyyV3NTW0GQR1XS
GI-ME-N MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LsZWlEPTB;NT6zPVY5OSEQvF2= NEXpVplUSU6JRWK=
NCI-H2122 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTXe|ZSUUN3ME21MlQ6Ozl5IN88US=> Mkn4V2FPT0WU
NCI-H1793 NIn0S2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTVwNke1PVMh|ryP NGf5UolUSU6JRWK=
C2BBe1 NFTLTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n6U2lEPTB;NT63NFA5QCEQvF2= MYnTRW5ITVJ?
TE-12 M4PxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP3UIRKSzVyPUWuPFA2PTZizszN M1S1XXNCVkeHUh?=
LCLC-103H MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTVwOUG3JO69VQ>? M1nDS3NCVkeHUh?=
A673 NY\Uc3loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfKTWM2OD13LkmxPVMzKM7:TR?= NFSwNopUSU6JRWK=
BB30-HNC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfIUGdRUUN3ME21Mlk5OzZizszN NGTJeodUSU6JRWK=
SF295 MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH1TWM2OD14LkCwOFIzKM7:TR?= NI[wboNUSU6JRWK=
KU-19-19 MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXz[pZKSzVyPU[uNFE4OzFizszN NV;4[YlkW0GQR1XS
CFPAC-1 NYjJdnk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHtTWM2OD14LkC0OFQ{KM7:TR?= NIHG[29USU6JRWK=
LoVo NUX6[IZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWyVI1KSzVyPU[uNFUxPjNizszN NXy2UW9CW0GQR1XS
8505C MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYraRpFEUUN3ME22MlA4PTd|IN88US=> Mmq1V2FPT0WU
GMS-10 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHsTWM2OD14LkG1NFAzKM7:TR?= Moe3V2FPT0WU
Ca9-22 M4f5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j1dGlEPTB;Nj6xOlcyKM7:TR?= MWDTRW5ITVJ?
DOK M2TJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSwfVRwUUN3ME22MlIzODd{IN88US=> MYnTRW5ITVJ?
FADU NILDWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;2TWM2OD14LkK2NFM6KM7:TR?= NIjUSGpUSU6JRWK=
BxPC-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vmV2lEPTB;Nj6yO|MzKM7:TR?= MVLTRW5ITVJ?
CAL-33 NY\WOY5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTZwMkmyNFEh|ryP NWDUeld{W0GQR1XS
SHP-77 NWrObHB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP4TWM2OD14LkOxOVEzKM7:TR?= NH7DUpBUSU6JRWK=
LXF-289 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLKbmNKSzVyPU[uN|M1PTVizszN M1rQfnNCVkeHUh?=
GB-1 M{LteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTZwM{iyJO69VQ>? MnT4V2FPT0WU
KS-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHmySVFKSzVyPU[uN|g1PDdizszN M1rZTXNCVkeHUh?=
D-502MG MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;xTWM2OD14LkSyN|c3KM7:TR?= M3LVS3NCVkeHUh?=
LAN-6 M{XoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPSV3NPUUN3ME22MlUyODJ|IN88US=> MUfTRW5ITVJ?
H-EMC-SS MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPEcmNKSzVyPU[uOVYyPDdizszN MUDTRW5ITVJ?
LC-2-ad NInWOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n6T2lEPTB;Nj62NFA4PiEQvF2= M1zv[3NCVkeHUh?=
NCI-H1693 NFez[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHDNndkUUN3ME22MlYzOjF3IN88US=> M2nzZXNCVkeHUh?=
SK-N-FI NHXw[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jsOmlEPTB;Nj63OVA1PCEQvF2= MUTTRW5ITVJ?
D-423MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmyWnBKSzVyPU[uO|YyOTdizszN MoC0V2FPT0WU
KNS-42 NITERYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXLTWM2OD14Lke4NVk4KM7:TR?= NHfCclFUSU6JRWK=
GCT MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTZwOUO4JO69VQ>? M1v4bnNCVkeHUh?=
DSH1 NEHqR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu4S2xRUUN3ME23MlA3OzNizszN NH\DOlVUSU6JRWK=
D-247MG MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTdwMEe4PFEh|ryP NWXpTXpoW0GQR1XS
NCI-SNU-5 NEnWeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTdwMUizO|Eh|ryP NWW0fJRMW0GQR1XS
TE-6 M{XTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK4Oot4UUN3ME23MlIxPjBzIN88US=> NYHm[|dNW0GQR1XS
NOMO-1 Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnEe|l7UUN3ME23MlIzOTJ5IN88US=> M4e4V3NCVkeHUh?=
NB17 NHzaRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCzTWM2OD15LkOwN|A6KM7:TR?= Mk\YV2FPT0WU
EW-22 NFjGeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDMXm9KSzVyPUeuN|Q{PDhizszN M4f1OnNCVkeHUh?=
EW-13 NHq3bVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X5ZmlEPTB;Nz6zOVE3OiEQvF2= MmKxV2FPT0WU
DOHH-2 MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPrdJpsUUN3ME23MlQ1ODJizszN MkfNV2FPT0WU
TGBC1TKB NXv5fYdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTpOZV6UUN3ME23MlQ6QDl7IN88US=> NYP4TXhvW0GQR1XS
GR-ST MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTdwNUK1PVQh|ryP MYXTRW5ITVJ?
KYSE-520 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTdwNUW1NVUh|ryP NGfx[plUSU6JRWK=
CAPAN-1 NGLSV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;Dd5d5UUN3ME23MlU6PTFizszN MXrTRW5ITVJ?
HCE-4 NW\RSo9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fRdGlEPTB;Nz62NlI4QSEQvF2= M323OHNCVkeHUh?=
MLMA Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLYTWM2OD15Lk[yPVU4KM7:TR?= M2fyRnNCVkeHUh?=
HT-144 MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:wfGlEPTB;Nz62OVM3QCEQvF2= M{\6WHNCVkeHUh?=
KYSE-180 M4P5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j1NmlEPTB;Nz63NVE3QSEQvF2= NIrado9USU6JRWK=
TE-5 NH[xfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\kUWlEPTB;Nz65OVk4OSEQvF2= MVTTRW5ITVJ?
IGROV-1 NHHR[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\aT2lEPTB;Nz65PFU2OSEQvF2= MorKV2FPT0WU
NCI-H1581 MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm0TWM2OD16LkCxNkDPxE1? NWXYT2hqW0GQR1XS
SW1990 MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHPbGFyUUN3ME24MlA1PjV7IN88US=> NIO5PIFUSU6JRWK=
EFM-19 MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;oc4g4UUN3ME24MlA5PTR3IN88US=> Mn3EV2FPT0WU
OGR-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRThwNEOwNlMh|ryP NFLjS4FUSU6JRWK=
U-118-MG MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO3NW1JUUN3ME24MlQ{PDZ|IN88US=> MWTTRW5ITVJ?
SK-OV-3 NVfpOotST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HBU2lEPTB;OD60Olc3PSEQvF2= M4fTRnNCVkeHUh?=
KNS-62 NXPJRZNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;BPJJKSzVyPUiuOVE4PjFizszN Mlm5V2FPT0WU
GOTO MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXZcY06UUN3ME24MlU4PjN3IN88US=> NF\zbnFUSU6JRWK=
8305C NHPQXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLjTWM2OD16LkewOFg1KM7:TR?= NH;kRYtUSU6JRWK=
RPMI-2650 NFezUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[xcI9KSzVyPUiuO|E6PTVizszN NF;WepFUSU6JRWK=
NEC8 NXnMc|ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvkTWM2OD16Lke0N|A4KM7:TR?= NUfWPXFvW0GQR1XS
KYSE-450 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTBcFFKSzVyPUiuPFY2PDhizszN MYTTRW5ITVJ?
RMG-I NXf0XZJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXGTWM2OD17LkG0NFU5KM7:TR?= NXjZc49pW0GQR1XS
CAKI-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLrTJJHUUN3ME25MlMyQTd7IN88US=> NWPzNnR3W0GQR1XS
KYSE-510 NGXEZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTlwM{W3O|gh|ryP M3rFZ3NCVkeHUh?=
A4-Fuk M1jOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C2eGlEPTB;OT6zOlcxOSEQvF2= NHTu[pNUSU6JRWK=
AN3-CA NGnudYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHixZmRKSzVyPUmuOFU1PDRizszN NXzmcYgyW0GQR1XS
SK-N-DZ NHfRSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXlTWM2OD17LkeyPFQ6KM7:TR?= M{nUfXNCVkeHUh?=
HSC-2 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojNTWM2OD17Lke2OlI6KM7:TR?= MU\TRW5ITVJ?
EW-1 NFrKXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDnTWM2OD17Lke5N|Y6KM7:TR?= NGH1c5FUSU6JRWK=
D-566MG NHP5XpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrYTWM2OD17LkizOlY1KM7:TR?= NWLHXJc{W0GQR1XS
COLO-792 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnOyTWM2OD17Lkm4O|Q3KM7:TR?= MkLXV2FPT0WU
TE-10 M1PReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jKSWlEPTB;MUCuNFM6PiEQvF2= NGK2U2tUSU6JRWK=
NCI-H650 NVX2V4xFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v4NWlEPTB;MUCuOFI5PiEQvF2= MnjEV2FPT0WU
U-266 MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fSV2lEPTB;MUCuOFU2KM7:TR?= NUTrPFc6W0GQR1XS
Detroit562 Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLCVGJKUUN3ME2xNU4xPTF3IN88US=> M4XqdnNCVkeHUh?=
NH-12 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTFzLkG0OFYh|ryP NXLrdnZvW0GQR1XS
CO-314 MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nRS2lEPTB;MUGuNlg1OiEQvF2= NIjqbG9USU6JRWK=
IST-MEL1 NYW5UIo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInxbJVKSzVyPUGxMlU{OjNizszN Mnf3V2FPT0WU
KNS-81-FD M2T0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXHVlRKSzVyPUGxMlU2OjdizszN NVPUcZZFW0GQR1XS
SW1463 MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDoS25KSzVyPUGxMlU6QDlizszN MYXTRW5ITVJ?
NCI-H23 NYLnZoRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjhSYM{UUN3ME2xNU43PTV{IN88US=> MWXTRW5ITVJ?
SK-MEL-2 Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLPTWM2OD1zMT63NVk4KM7:TR?= NULS[HA1W0GQR1XS
NB13 NXXpdZl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHsTWM2OD1zMj6xOFk2KM7:TR?= MojHV2FPT0WU
Daoy M3vIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPoZYpKSzVyPUGyMlI5PTZizszN NUTINlVsW0GQR1XS
NCI-H1623 M4HKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF{LkO4NFEh|ryP Mmj3V2FPT0WU
NMC-G1 M3rvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M161WWlEPTB;MUKuO|E4KM7:TR?= MVTTRW5ITVJ?
DK-MG M4jjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3PSpVlUUN3ME2xNk46PDh{IN88US=> NEC3OJRUSU6JRWK=
TCCSUP M4rmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;JdmRUUUN3ME2xN{4yOjh2IN88US=> NFiwbYtUSU6JRWK=
SCC-15 MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjGOm1KSzVyPUGzMlI3PTFizszN MUHTRW5ITVJ?
NOS-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELQcY9KSzVyPUGzMlI5QTNizszN M{TDfHNCVkeHUh?=
RH-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXmVHROUUN3ME2xN{4{ODN5IN88US=> NFvZOFNUSU6JRWK=
SK-MEL-3 MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF|LkO3Nlgh|ryP MoD5V2FPT0WU
NB5 NFv0[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;JU4NKSzVyPUGzMlQxPjdizszN MXTTRW5ITVJ?
SNU-387 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXjTm56UUN3ME2xN{42ODd{IN88US=> NYPQUY9NW0GQR1XS
CAL-120 NUnHZpJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXKZoFxUUN3ME2xN{43PzF6IN88US=> MmrTV2FPT0WU
Mo-T NG\LXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF|LkewO{DPxE1? NF7rUpVUSU6JRWK=
LNCaP-Clone-FGC Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TaWmlEPTB;MUOuO|k6OiEQvF2= Mm\NV2FPT0WU
CAN NVXjPItbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDVdZZOUUN3ME2xOE4xOjh6IN88US=> M3TTRnNCVkeHUh?=
SK-MEL-30 M{jCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHyTWM2OD1zND6wOlMh|ryP NH\wRYpUSU6JRWK=
COLO-678 NF7qZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL4WmtKSzVyPUG0MlA5OjJizszN M2DEbXNCVkeHUh?=
SCC-9 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF2LkGwNlEh|ryP NG\hdXdUSU6JRWK=
KINGS-1 NITlRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELibYxKSzVyPUG0MlE1ODJizszN NGLLVGNUSU6JRWK=
SL-513 Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF2LkG4O{DPxE1? MX7TRW5ITVJ?
HLE Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXhVlRKSzVyPUG0MlM5PTJizszN NYnjXFVXW0GQR1XS
SW1573 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHxSVRKSzVyPUG0MlQ1OzVizszN MUDTRW5ITVJ?
KYSE-140 NGfSfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfiTWM2OD1zND62N|I4KM7:TR?= NX\leFlSW0GQR1XS
SK-PN-DW NFrxWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1eyb2lEPTB;MUSuPFAxOSEQvF2= M3Hy[XNCVkeHUh?=
A253 NEnaeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF3LkC2NlUh|ryP MkPZV2FPT0WU
CAL-12T M{PuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nmfGlEPTB;MUWuOFY3OiEQvF2= MkHZV2FPT0WU
COLO-679 M{e3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfTR|RKSzVyPUG1Mlc3QDNizszN NHTMT2JUSU6JRWK=
UACC-257 NUnke3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\5TWM2OD1zNj6xNlAyKM7:TR?= NIPFOJdUSU6JRWK=
U-87-MG NIfMOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF4LkO1NlMh|ryP M2O0enNCVkeHUh?=
HCC1806 MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnncItKSzVyPUG2MlcxPzFizszN NHzDTm1USU6JRWK=
NCI-H2170 NXS3eHRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H6dWlEPTB;MUeuNlQ1QCEQvF2= MYHTRW5ITVJ?
AGS NILMZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjqVo9wUUN3ME2xO{4{QDB6IN88US=> MnnEV2FPT0WU
MEL-HO NFrMboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXiOHRKSzVyPUG3Mlc2ODNizszN M136[nNCVkeHUh?=
SW48 Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF5Lke3NVYh|ryP MnTRV2FPT0WU
HuP-T4 NVjHXZd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDDZZBKSzVyPUG4MlAzODZizszN M4DZT3NCVkeHUh?=
NCI-H720 NU\MXHZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml74TWM2OD1zOD6xOFAzKM7:TR?= M17oS3NCVkeHUh?=
RCC10RGB M{nSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK0W5FKSzVyPUG4MlE3QTdizszN MWXTRW5ITVJ?
HD-MY-Z M1\nc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF6LkKyOVQh|ryP MYfTRW5ITVJ?
A427 M2XQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XZW2lEPTB;MUiuOVA6PCEQvF2= NVrpOZhoW0GQR1XS
HCC2998 NVrodHlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DYNGlEPTB;MUiuOlA2OSEQvF2= NX;w[4R[W0GQR1XS
EPLC-272H MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF7LkC0N|Qh|ryP MWHTRW5ITVJ?
C32 MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37afmlEPTB;MUmuNFQ2KM7:TR?= NE\DclVUSU6JRWK=
UMC-11 NFjBOJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\HUoNKSzVyPUG5MlIyOjNizszN NWL2WmlIW0GQR1XS
CaR-1 MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NImyWpJKSzVyPUG5MlY5ODRizszN MnK2V2FPT0WU
KYSE-410 NYrEenY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT1[|NEUUN3ME2xPU46OTN7IN88US=> NIjycVRUSU6JRWK=
HuCCT1 Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJyLk[yPVQh|ryP NUPFcVBFW0GQR1XS
LB996-RCC M2rmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLJTZdKSzVyPUKwMlcyPjhizszN M2jLV3NCVkeHUh?=
KYSE-70 NWK5eppFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJyLkiwOVkh|ryP M2qzPXNCVkeHUh?=
CAL-72 M2T4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXhOnlKSzVyPUKwMlkyPSEQvF2= MoP1V2FPT0WU
Capan-2 NXmycJVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\KdVlKSzVyPUKxMlA1OTNizszN M1XwOnNCVkeHUh?=
PANC-08-13 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXtOFhwUUN3ME2yNU4zPTF3IN88US=> NELzVlhUSU6JRWK=
SBC-1 NF7BdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fFW2lEPTB;MkGuN|A5OSEQvF2= M4nkcHNCVkeHUh?=
MFM-223 NWPYXoF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z2ZmlEPTB;MkGuN|M1OiEQvF2= NGSzWoRUSU6JRWK=
BB49-HNC MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXBTFhKSzVyPUKxMlU4OTZizszN M37uUXNCVkeHUh?=
SH-4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTUTpRqUUN3ME2yNU43PjF6IN88US=> MXPTRW5ITVJ?
HuO9 M37jO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXZTWM2OD1{MT65PFI2KM7:TR?= NI\5WFVUSU6JRWK=
AM-38 M1HRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3MWWlKSzVyPUKyMlA1QDVizszN NXjSS5VjW0GQR1XS
A431 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID1W|NKSzVyPUKzMlIyOTlizszN M2P5SXNCVkeHUh?=
YAPC NUXHXY5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M32zVmlEPTB;MkOuNlY2OSEQvF2= MVnTRW5ITVJ?
LU-139 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTITWM2OD1{Mz60PFA6KM7:TR?= MV;TRW5ITVJ?
HEC-1 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvsPXBKSzVyPUKzMlQ6OzdizszN M4mwVnNCVkeHUh?=
SCC-25 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSwTWM2OD1{ND6zNFA3KM7:TR?= Mlu4V2FPT0WU
HT-29 NHjtdppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ2LkO4NlMh|ryP NYTIXow{W0GQR1XS
PC-14 MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ2Lk[1O|Eh|ryP NW\pflQyW0GQR1XS
Calu-6 NF74[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ3LkWwO|Eh|ryP Mnv6V2FPT0WU
SJRH30 M{T5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W1OWlEPTB;MkWuOlQ6PiEQvF2= NFfiU|hUSU6JRWK=
ChaGo-K-1 M{LNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2WzOWlEPTB;Mk[uNVYzQSEQvF2= M1v2R3NCVkeHUh?=
IA-LM M1XpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1yxT2lEPTB;Mk[uN|Y1PSEQvF2= NXq1fFd2W0GQR1XS
GP5d MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTkTZRuUUN3ME2yOk41PDlzIN88US=> NES0VlZUSU6JRWK=
NCI-H2291 M3\1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LvWWlEPTB;Mk[uOlU1OSEQvF2= NH7WeXJUSU6JRWK=
BALL-1 NH3Se49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:2OGxEUUN3ME2yOk46Ozl5IN88US=> MVzTRW5ITVJ?
HCC1954 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[0NIxKSzVyPUK2Mlk5ODhizszN MWTTRW5ITVJ?
NCI-H2452 Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrlVXZKSzVyPUK3MlQyPjNizszN M2DQTHNCVkeHUh?=
LU-99A M3vlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm2NlhKSzVyPUK3MlU2QDJizszN MnzBV2FPT0WU
NTERA-S-cl-D1 NXnW[oh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P1V2lEPTB;MkeuO|I6QSEQvF2= NH\ZZ2RUSU6JRWK=
PANC-10-05 M{DIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXZTIZuUUN3ME2yO{44Pzd3IN88US=> M4PENHNCVkeHUh?=
NCI-H2405 Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXnTWM2OD1{Nz65N|g4KM7:TR?= NFH1UYRUSU6JRWK=
MDA-MB-415 MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf3PY5KSzVyPUK4MlQyOzdizszN M1XYSXNCVkeHUh?=
NCI-H2342 NF32[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXhOGFIUUN3ME2yPE42OjhzIN88US=> NHe5RmVUSU6JRWK=
TGBC24TKB NWDWWWtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvLTWM2OD1{OD63NVE4KM7:TR?= M2HJSHNCVkeHUh?=
LU-134-A MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrZTWM2OD1{OD65NlYyKM7:TR?= MnHTV2FPT0WU
SCC-4 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHrTWM2OD1|MT6wOFk1KM7:TR?= NIf5bXpUSU6JRWK=
Saos-2 NUjRSlVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTxPG9KSzVyPUOxMlk{ODZizszN MmXvV2FPT0WU
RERF-LC-MS M{TzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTRS2ZSUUN3ME2zNk45OjNzIN88US=> Mn3NV2FPT0WU
M14 M4fXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DwNGlEPTB;M{KuPVc3PCEQvF2= NHPHclFUSU6JRWK=
HPAF-II NHT6U|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO4dHNKSzVyPUOzMlUxOTFizszN MWLTRW5ITVJ?
NCI-H1755 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XkVmlEPTB;M{SuN|MxPSEQvF2= NV;HfYRIW0GQR1XS
D-392MG NHu2OY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT5VI9KSzVyPUO1Mlg3PzRizszN NWi4emF2W0GQR1XS
A704 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\LS2lEPTB;M{[uNFQzPyEQvF2= NEHm[HhUSU6JRWK=
CP50-MEL-B M1r1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGezOohKSzVyPUO2MlE6OTFizszN MULTRW5ITVJ?
EW-18 NHi2eItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XGfGlEPTB;M{[uOFUzKM7:TR?= NGO2O4xUSU6JRWK=
WM-115 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoOwTWM2OD1|Nj64NFk6KM7:TR?= NXjkU5llW0GQR1XS
LU-65 M1;lPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LIVmlEPTB;M{euNVQyPyEQvF2= MW\TRW5ITVJ?
NCI-H1563 NG\PW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTN5LkK0PFQh|ryP NF7zWGRUSU6JRWK=
DBTRG-05MG M37Z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu3ZW1KSzVyPUO4MlA3QTFizszN MX3TRW5ITVJ?
NCI-H630 NXPhWVM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{KzT2lEPTB;M{iuOFcyPCEQvF2= MojOV2FPT0WU
NCI-H1155 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHFfVFKSzVyPUO5MlI1OiEQvF2= M3jFW3NCVkeHUh?=
OVACR-3 M3:ycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrHblRKSzVyPUO5MlkyQTVizszN MYTTRW5ITVJ?
OAW-42 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTRyLkSyOVgh|ryP NFu0ZVRUSU6JRWK=
JVM-2 NHXO[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e4WGlEPTB;NEGuNlQyPSEQvF2= MYTTRW5ITVJ?
C3A NV64e5lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme5TWM2OD12MT6zOFQ4KM7:TR?= M1TIXXNCVkeHUh?=
HT55 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnjR4lZUUN3ME20Nk4zQDRzIN88US=> NVrzPHJoW0GQR1XS
OVCAR-4 NUnLOlJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzPTWM2OD12Mj6yPVc1KM7:TR?= MmjJV2FPT0WU
MEG-01 NGrw[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrVbJQ4UUN3ME20Nk41PjF4IN88US=> NUS5WlI{W0GQR1XS
NCI-H82 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr5XZpKSzVyPUSzMlk5QTJizszN M1G0fnNCVkeHUh?=
JEG-3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX5XYVJUUN3ME20OE46PDdizszN MVrTRW5ITVJ?
BPH-1 NX\zS5RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS4TWM2OD12Nj6zPVk5KM7:TR?= NIfsPZNUSU6JRWK=
MPP-89 NGPwfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3vTWM2OD12Nz6yPFk5KM7:TR?= MWPTRW5ITVJ?
ALL-PO M1HVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG3TGFKSzVyPUS3MlQyQDhizszN MmX2V2FPT0WU
HT NV7DVJJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTR5LkS5NkDPxE1? M3riOXNCVkeHUh?=
NCI-H2347 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fGbmlEPTB;NEiuNFcyPSEQvF2= M4T1XXNCVkeHUh?=
A2780 Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17GZWlEPTB;NEmuOFIzQCEQvF2= NHPGUYhUSU6JRWK=
KARPAS-299 M16wc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjjTWM2OD12OT61NVE6KM7:TR?= MWjTRW5ITVJ?
NCI-H1651 NXjGSHVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfKTWM2OD12OT64PFIyKM7:TR?= MYTTRW5ITVJ?

... Click to View More Cell Line Experimental Data
In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]
+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]
+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]
+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing. 		6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl
CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03709680 Not yet recruiting Solid Tumors|Ewing Sarcoma|Rhabdoid Tumor|Rhabdomyosarcoma|Neuroblastoma|Medulloblastoma Pfizer February 5 2019 Phase 1
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer January 7 2019 Phase 2
NCT03691493 Not yet recruiting Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Bone|Progesterone Receptor Positive|Prognostic Stage IV Breast Cancer AJCC v8 Emory University|Pfizer December 1 2018 Phase 2
NCT03530696 Not yet recruiting HER2-positive Breast Cancer|Breast Cancer|Breast Cancer Stage|Recurrent Breast Cancer|Metastatic Breast Cancer|HER2 Positive Breast Carcinoma University of Arizona|Pfizer November 30 2018 Phase 2
NCT03531645 Not yet recruiting Malignant Neoplasms of Female Genital Organs M.D. Anderson Cancer Center|AstraZeneca|Pfizer November 2018 Phase 2
NCT03644186 Not yet recruiting Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer International Breast Cancer Study Group|Pfizer|Hoffmann-La Roche October 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

  • Most Potent CDK Inhibitor

    LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).

  • Newest CDK Inhibitor

    NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products3

  • SU9516 New

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306 New

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A New

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

  • abemaciclib mesylate (LY2835219)

    abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID